Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287235 · ClinicalTrials.gov registry record · NA
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
A NA study, sponsored by Vantive Health.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT00287235 is a NA study that has completed, run by Vantive Health. The registered enrollment target is 70 participants.
The verdict
NCT00287235, a NA study, has completed, sponsored by Vantive Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
The primary objective of the study was to compare the efficacy, safety and tolerability of Extracorporeal Albumin Dialysis (ECAD) using the Molecular Adsorbent Recirculating System (MARS®) device in improving severe HE by 2 grades compared to Standard Medical Therapy (SMT) in patients with chronic End Stage Liver Disease (ESLD) during a 5 day study period.
Interventions
- DEVICE MARS
- DRUG Standard Medical Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287235
The ClinicalTrials.gov registry entry for NCT00287235 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MARS is the first listed.
NCT00287235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287235 about?
NCT00287235 is a clinical study titled "Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)". The primary objective of the study was to compare the efficacy, safety and tolerability of Extracorporeal Albumin Dialysis (ECAD) using the Molecular Adsorbent Recirculating System (MARS®) device in improving severe HE by 2 grades compared to Standard Medical Therapy (SMT) in patients with chronic E...
What is the current status of trial NCT00287235?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2000-09. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00287235?
The interventions under investigation include: MARS (DEVICE), Standard Medical Therapy (DRUG).
Who is sponsoring clinical trial NCT00287235?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.